STOCKS TELEGRAPH

Tag: ZCMD

  • Zhongchao Inc. (ZCMD) Surges in Broader Chinese Low Float Rush

    Zhongchao Inc. (NASDAQ: ZCMD) experienced a remarkable surge in its stock price on Wednesday, initially rising by 22% during regular trading hours. However, the excitement didn’t stop there. In the after-hours session, the stock, driven by what appears to be a bullish frenzy, skyrocketed by an additional 30.5%, leaving investors buzzing with anticipation.

    Surge Amidst Uncertainty

    Zhongchao Inc., a prominent holding company, is known for its involvement in healthcare information, education, and training services. Its operations span across the Services and Drugs segments, offering a wide array of online and onsite healthcare services, education programs, and training products.

    Despite this surge, there seems to be a conspicuous absence of concrete news driving this rapid increase, leaving many investors wary of a potential profit-taking dip in the days to come. However, for now, bullish investors are content riding the wave of optimism.

    Market Dynamics and Concerns

    This surge coincides with a broader interest among traders, particularly in Chinese stocks, during the after-hours session. Stocks like ZCMD, characterized by their low float, become particularly susceptible to volatile price movements, making them enticing targets for short-term trading strategies.

    However, trading volume remains notably below average levels, prompting concerns among market observers. The opportunity, it seems, lies primarily within the extended hours trading window.

    Earlier Milestones

    Earlier last month, Zhongchao Inc. announced a significant milestone in its efforts to provide healthcare assistance to low-income patients suffering from Systemic Lupus Erythematosus (SLE). Through its subsidiary, Shanghai Zhongxin Medical Technology Co., Ltd., the company successfully provided medication assistance to over 7,000 SLE patients, alleviating their financial burdens associated with long-term treatment.

    This initiative points to Zhongchao’s commitment to leveraging its technical expertise to address critical healthcare needs. As investors navigate the volatile terrain of after-hours trading, the future trajectory of ZCMD remains uncertain, with market dynamics and underlying fundamentals shaping its course in the days ahead.

  • Zhongchao Inc. (ZCMD) stock Skyrockets Premarket After Plunging to New Low

    On March 14, Zhongchao Inc. (ZCMD) stock skyrocketed in the premarket to add an immense 60.00%. Thus, at the time of writing, the stock was trading at a price of $1.68 per share in the premarket. The volume of the shares exchanged was 754.2K at the time. There is no recent official announcement or SEC filing from the company.

    In the previous trading session on Friday, ZCMD fluctuated between $1.05 and $1.75 to report its new 52-week low of $1.05. The stock closed the session with a huge loss of 38.24% at a price of $1.05 per share.

    The healthcare information, education, and training services provider, Zhongchao Inc. is based in China.

    ZCMD’s Trend Reversal

    As the stock markets continued to suffer from the frenzy caused by the Russia-Ukraine conflict, ZCMD shared a similar fate. With healthcare stocks taking a harsh hit, ZCMD had also been going down since March 08. Continuing the downfall, the stock plunged to its new 52-week low of $1.05 on Friday. Consequently, the stock rebounded in the premarket session today. Since there is no recent news from the company, it seems the new low gave way to the recovery today. It is most likely that investors saw the new low price of the stock as a good opportunity to stock up. Hence, the stock rebounded and surged up in the premarket today due to external factors.

    It is unclear as to how long the current bullish momentum will continue as the market is highly volatile but for now, the stock is up for some good gains.

    Company News

    On October 29, the company announced updates regarding its self-developed patient management system. ZCMD’s patient management system improves the Duration of Therapy by 40.4% for patients with liver cancer. Therefore, contributing to maximum drugs efficiency, successful treatment, and extended patient survival terms.

    Source: HarmoniMD

    As per The Global Cancer Observatory, China had 400,000 new liver cancer cases in 2020. The main treatment of liver cancer currently includes surgical resection, interventional therapy, radiotherapy, and transplant. All these treatments have limitations specifically adverse reactions during the systemic therapies usually decrease life quality and negatively effects treatment. So, ZCMD closely monitors and deals with adverse reactions through its patient management system. Follow-up, psychological counseling, drugs usage reminder, and patient supervision all are done through the system.

    On September 17, the company announced the launch of its multidisciplinary treatment (MDT) clinical thinking training platform for hematology. This platform provides a channel for learning multidisciplinary thinking skills online. Hence, improving diagnosis and treatment along with efficiency.

  • Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Pre-Market Cues: 28 Stocks Roaring for Change On December 18th

    Seneca Biopharma Inc. (SNCA), a Biotechnology company, rose about 0.2% at $0.96 in pre-market trading Friday after declaring merger agreement with Leading BioSciences, Inc. under which a wholly owned subsidiary of Seneca will merge with LBS in an all-stock transaction.

    Palantir Technologies Inc. (PLTR) lost over -3.97% at $26.15 in pre-market trading Friday December 18, 2020 after reporting that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

    Atossa Therapeutics Inc. (ATOS) stock plunged -0.02% to $0.86 in the pre-market trading following its declaration of pricing of $14.0 million registered direct offering priced at-the-market. The most recent rating by Maxim Group, on January 26, 2018, is a Buy.

    Virgin Galactic Holdings Inc. (NYSE: SPCE) shares are trading down -6.27% at $23.9 at the time of writing. The company recently revealed an update following its test flight on December 12, 2020. Company’s 52-week ranged between $9.06 to $42.49. Analysts have a consensus price target of $19.

    BlackBerry Limited (BB), a Software – Infrastructure company, dropped about -4.36% at $7.9 in pre-market trading Friday after releasing its financial results for the three months ended November 30, 2020

    Before the trading started on December 18, 2020, Uxin Limited (UXIN) is up 4.5% to reach $1.16 following its announcement of unaudited financial results for the quarter ended September 30, 2020. It has been trading in a 52-week range of $0.72 to $3.07.

    Coeur Mining Inc. (CDE) stock plunged -2.98% to $10.76 in the pre-market trading. The firm recently revealed details of the expansion of its Rochester silver-gold mine in Nevada, reflecting significant reserve growth and the benefits of a larger-scale expansion project. The most recent rating by Noble Capital Markets, on September 14, 2020, is an Outperform.

    Novan Inc. (NASDAQ: NOVN) shares are trading up 6.25% at $0.68 at the time of writing. The company lately reported that it has enrolled 525 patients of the approximately 850 patients expected to enroll in the B-SIMPLE4 pivotal Phase 3 clinical study of SB206. Company’s 52-week ranged between $0.22 to $3.72.

    CNS Pharmaceuticals Inc. (CNSP), a Biotechnology company, rose about 15.2% at $2.88 in pre-market trading Friday after announcing FDA approval of IND application for its brain cancer drug candidate Berubicin.

    United States Steel Corporation (X) stock moved down -4.26 percent to $17.77 in the pre-market trading after reporting that fourth quarter 2020 adjusted EBITDA is expected to be approximately $55 million and expected fourth quarter 2020 adjusted diluted loss per share to be approximately ($0.85).

    BioCardia Inc. (BCDA) lost over -6.09% at $4.01 in pre-market trading Friday December 18, 2020 following an announcement from the firm that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial.

    Before the trading started on December 18, 2020, Ampio Pharmaceuticals Inc. (AMPE) is up 8.43% to reach $1.93 after revealing the completion of its Phase I clinical trial and initiation of the first steps for a global Phase II clinical trial for intravenous (“IV”) Ampion treatment in COVID-19 patients. It has been trading in a 52-week range of $0.31 to $1.69.

    Drive Shack Inc. (NYSE: DS) shares are trading up 5.47% at $3.47 at the time of writing following the opening of its 65,000-square-foot entertainment golf venue located in Orlando. Company’s 52-week ranged between $0.86 to $4.19. Analysts have a consensus price target of $4.

    IZEA Worldwide Inc. (IZEA) tumbled over -3.7% at $1.04 in pre-market trading today. The company recently reported that it has just been awarded a mid-six figure contract from a Fortune 500 Manufacturer.

    Exela Technologies Inc. (XELA), a Software – Application company, rose about 81.87% at $0.66 in pre-market trading Friday after declaring that it has entered into a 5-year, $145 million term loan facility with Angelo Gordon, a global alternative investment firm.

    FedEx Corporation (FDX) stock moved down -2.89 percent to $283.8 in the pre-market trading after declaring strong results for the quarter ended November 30.

    Guardion Health Sciences Inc. (GHSI) stock plunged -2.13% to $0.23 in the pre-market trading. The firm recently declared progress on the introduction of its new vision support/energy drink, Epiq-V, which is under development for the United States and international markets.

    Amyris Inc. (NASDAQ: AMRS) shares are trading up 3.68% at $4.23 at the time of writing. Company’s 52-week ranged between $1.40 to $6.07. Analysts have a consensus price target of $3.35.

    Mereo BioPharma Group plc (MREO), a Biotechnology company, rose about 40.27% at $3.1 in pre-market trading Friday following the declaration of a license and collaboration agreement with Ultragenyx Pharmaceutical Inc. (RARE), for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

    Surface Oncology Inc. (SURF) gained over 17.51% at $10.0 in pre-market trading Friday December 18, 2020 after revealing exclusive license agreement with GSK for novel immunotherapy program.

    Neovasc Inc. (NVCN) is down more than -8.52% at $0.91 in pre-market hours Friday December 18, 2020 after reporting the publication of peer-reviewed article in EuroIntervention. The stock had jumped over 3.61% to $0.99 in the last trading session.

    BioLineRx Ltd. (BLRX) tumbled over -1.1% at $2.7 in pre-market trading today. The firm lately declared final results from Phase 2a COMBAT/KEYNOTE-202 triple combination study of Motixafortide in second line Metastatic Pancreatic Cancer (PDAC).

    VYNE Therapeutics Inc. (VYNE), a Biotechnology company, rose about 8.05% at $1.88 in pre-market trading Friday after declaring the successful completion of its End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).

    Before the trading started on December 18, 2020, Mesoblast Limited (MESO) is down -26.75% to reach $9.94 after announcing an update on COVID-19 ARDS trial. It has been trading in a 52-week range of $3.12 to $21.28.

    Applied DNA Sciences Inc. (APDN) stock plunged -12.02% to $5.49 in the pre-market trading after reporting consolidated financial results for the full fiscal year and quarter ended September 30, 2020. The most recent rating by H.C. Wainwright, on July 20, 2020, is a Buy.

    Conformis Inc. (NASDAQ: CFMS) shares are trading up 3.8% at $0.6693 at the time of writing. The firm lately revealed the U.S. commercial launch of the Company’s new Cordera™ Match Hip System. Company’s 52-week ranged between $0.50 to $1.66.

    Auris Medical Holding Ltd. (EARS) grew over 1.5% at $2.7 in pre-market trading today. The company recently provided a business update related to the Company’s funding position, its AM-301 program for the protection against airborne pathogens and allergens and the ongoing strategy review process.

    Sonoma Pharmaceuticals Inc. (SNOA) stock moved up 19.79 percent to $9.14 in the pre-market trading following the announcement of partnership with Gabriel Science, LLC for dental.